Journal of Clinical Oncology, Vol 14, 1282-1290, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University

MP Mac Manus and RT Hoppe
Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA.

PURPOSE: To evaluate retrospectively the results of radiotherapy for 177 patients with stage I (n = 73 [41%]) and II (n = 104 [59%]) follicular small cleaved-cell and follicular mixed small cleaved-cell and large-cell non-Hodgkin's lymphoma (NHL) treated in the Department of Radiation Oncology, Stanford University between 1961 and 1994. PATIENTS AND METHODS: Histology was follicular small cleaved-cell in 101 (57%) cases and follicular mixed small cleaved-cell and large-cell in 76 (43%). Forty-five patients (25%) had staging laparotomy; 34 (19%) had extranodal involvement. All patients had received radiotherapy, either to one side of the diaphragm (involved or extended field) or to both sides (total lymphoid irradiation [TLI] or subtotal lymphoid irradiation [STLI]. Radiotherapy doses ranged from 35 to 50 Gy. RESULTS: The median follow-up duration was 7.7 years. The longest follow-up duration was 31 years. Actuarial survival rates at 5, 10, 15, and 20 years were 82%, 64%, 44%, and 35%, respectively. The median survival time was 13.8 years. At 5, 10, 15, and 20 years, 55%, 44%, 40%, and 37% of patients, respectively, were relapse-free. Only five of 47 patients who reached 10 years without relapse subsequently developed recurrence. Survival and freedom from relapse (FFR) were significantly worse for older patients. Relapse rates were lower following treatment on both sides of the diaphragm or staging laparotomy. Univariate analysis showed that youth and staging laparotomy were associated with significantly better survival and that FFR was better following treatment on both sides of the diaphragm or laparotomy. CONCLUSION: Radiotherapy remains the treatment of choice for early-stage low-grade follicular lymphomas. Patients who have remained free of disease for 10 years are unlikely to relapse.

This article has been cited by other articles:

				S. K. Luthy, A. K. Ng, B. Silver, K. O. Degnan, D. C. Fisher, A. S. Freedman, and P. M. Mauch Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma Ann. Onc., December 1, 2008; 19(12): 2043 - 2047. [Abstract] [Full Text] [PDF]

				A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up J. Clin. Oncol., June 20, 2007; 25(18): 2554 - 2559. [Abstract] [Full Text] [PDF]

				J. G. Gribben How I treat indolent lymphoma Blood, June 1, 2007; 109(11): 4617 - 4626. [Abstract] [Full Text] [PDF]

				P. Venugopal and S. A. Gregory Lymphoproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 265 - 297. [Full Text] [PDF]

				M. S. Kaminski, M. Tuck, J. Estes, A. Kolstad, C. W. Ross, K. Zasadny, D. Regan, P. Kison, S. Fisher, S. Kroll, et al. 131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma N. Engl. J. Med., February 3, 2005; 352(5): 441 - 449. [Abstract] [Full Text] [PDF]

				S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas, D. Podoloff, and M. Goris Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab J. Clin. Oncol., February 1, 2005; 23(4): 712 - 719. [Abstract] [Full Text] [PDF]

				J. M. Vose, P. J. Bierman, C. Enke, J. Hankins, G. Bociek, J. C. Lynch, and J. O. Armitage Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma J. Clin. Oncol., January 20, 2005; 23(3): 461 - 467. [Abstract] [Full Text] [PDF]

				R. Advani, S. A. Rosenberg, and S. J. Horning Stage I and II Follicular Non-Hodgkin's Lymphoma: Long-Term Follow-Up of No Initial Therapy J. Clin. Oncol., April 15, 2004; 22(8): 1454 - 1459. [Abstract] [Full Text] [PDF]

				B. D. Smith, E. J. Glusac, J. M. McNiff, G. L. Smith, P. W. Heald, D. L. Cooper, and L. D. Wilson Primary Cutaneous B-Cell Lymphoma Treated With Radiotherapy: A Comparison of the European Organization for Research and Treatment of Cancer and the WHO Classification Systems J. Clin. Oncol., February 15, 2004; 22(4): 634 - 639. [Abstract] [Full Text] [PDF]

				A. K. Gopal, T. A. Gooley, D. G. Maloney, S. H. Petersdorf, J. F. Eary, J. G. Rajendran, S. A. Bush, L. D. Durack, J. Golden, P. J. Martin, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis Blood, October 1, 2003; 102(7): 2351 - 2357. [Abstract] [Full Text] [PDF]

				O. W. Press, J. M. Unger, R. M. Braziel, D. G. Maloney, T. P. Miller, M. LeBlanc, E. R. Gaynor, S. E. Rivkin, and R. I. Fisher A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 Blood, September 1, 2003; 102(5): 1606 - 1612. [Abstract] [Full Text] [PDF]

				W. Hiddemann ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma Ann. Onc., August 1, 2003; 14(8): 1163 - 1164. [Full Text] [PDF]

				R.L.M. Haas, Ph. Poortmans, D. de Jong, B.M.P. Aleman, L.G.H. Dewit, M. Verheij, A.A.M. Hart, M.H.J. van Oers, M. van der Hulst, J.W. Baars, et al. High Response Rates and Lasting Remissions After Low-Dose Involved Field Radiotherapy in Indolent Lymphomas J. Clin. Oncol., July 1, 2003; 21(13): 2474 - 2480. [Abstract] [Full Text] [PDF]

				J. F. Seymour, B. Pro, L. M. Fuller, J. T. Manning, F. B. Hagemeister, J. Romaguera, M. A. Rodriguez, C. S. Ha, T. L. Smith, A. Ayala, et al. Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I-II Indolent Non-Hodgkin's Lymphoma J. Clin. Oncol., June 1, 2003; 21(11): 2115 - 2122. [Abstract] [Full Text] [PDF]

				P. McLaughlin Progress and Promise in the Treatment of Indolent Lymphomas Oncologist, June 1, 2002; 7(3): 217 - 225. [Abstract] [Full Text] [PDF]

				A. K. Gopal, J. G. Rajendran, S. H. Petersdorf, D. G. Maloney, J. F. Eary, B. L. Wood, T. A. Gooley, S. A. Bush, L. D. Durack, P. J. Martin, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma Blood, May 1, 2002; 99(9): 3158 - 3162. [Abstract] [Full Text] [PDF]

				S. Montoto, A. Lopez-Guillermo, A. Ferrer, M. Camos, A. Alvarez-Larran, F. Bosch, J. Blade, F. Cervantes, J. Esteve, F. Cobo, et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors Ann. Onc., April 1, 2002; 13(4): 523 - 530. [Abstract] [Full Text] [PDF]

				P. J. Lugtenburg, B. Löwenberg, R. Valkema, H.-Y. Oei, S. W. Lamberts, M. J. Eijkemans, W. L. van Putten, and E. P. Krenning Somatostatin Receptor Scintigraphy in the Initial Staging of Low-Grade Non-Hodgkin's Lymphomas J. Nucl. Med., February 1, 2001; 42(2): 222 - 229. [Abstract] [Full Text]

				C. Aristei and A. Tabilio Total-Body Irradiation in the Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoproliferative Diseases Oncologist, October 1, 1999; 4(5): 386 - 397. [Abstract] [Full Text]

				Y. K. Oh, C. S. Ha, B. I. Samuels, F. Cabanillas, M. A. Hess, and J. D. Cox Stages I–III Follicular Lymphoma: Role of CT of the Abdomen and Pelvis in Follow-up Studies Radiology, February 1, 1999; 210(2): 483 - 486. [Abstract] [Full Text]